NFL Drug Policy Faces Scrutiny After Fertility Medication Case

Kansas City Chiefs safety Nazeeh Johnson is suspended under the NFL’s performance-enhancing drug policy. He attributed his positive test to fertility medication used for personal reasons.

On October 10, 2023, the NFL confirmed the suspension, citing a violation of its anti-doping framework. Johnson stated, "I was taking the medication for personal reasons unrelated to football. I never intended to gain any competitive advantage."

Fertility medications, particularly those containing human chorionic gonadotropin (hCG), complicate anti-doping policies. HCG can mask performance-enhancing drugs while being prescribed for hormonal imbalances. The NFL Players Association (NFLPA) advises athletes to review the drug-testing policy before taking medications, yet Johnson's case raises questions about whether the policy adequately considers athletes' health needs.

Johnson's situation echoes past incidents. In 2015, Cleveland Browns cornerback Joe Haden received a four-game suspension after testing positive for Adderall without a therapeutic use exemption. Similarly, Golden Tate of the New York Giants appealed a four-game suspension in 2019, claiming a fertility treatment led to his positive test, but his appeal was denied.

The NFL’s policy, last revised in 2020, mandates immediate reporting of prescribed medications containing banned substances. Critics argue that it rigidly interprets intent versus effect. Adolpho Birch, the NFL’s Chief Legal Officer, defended the framework, stating, "Uniform standards are essential for fairness and integrity," while acknowledging that "exceptions require a high burden of proof."

The policy aims to deter violations, with players facing suspensions of up to six games for first-time offenses. However, the lack of nuance has led to calls for reform from within the NFLPA. George Atallah, the union’s assistant executive director, remarked in 2022, "We need a policy that reflects the realities of players’ lives off the field, not just their actions on it."

Legally, the NFL’s policy is supported by the collective bargaining agreement, limiting individual appeals unless procedural errors occur. Analysts note that reputational risks are significant for a league already criticized for its handling of mental health and substance use. Michael McCann, a sports law professor, noted, "Nazeeh Johnson’s story could be a flashpoint. The NFL has to weigh the public’s desire for accountability against its own duty to treat players as humans, not commodities."

Data from the U.S. Anti-Doping Agency (USADA) shows that hCG accounted for fewer than 2% of positive tests across U.S. sports in 2022. Experts suggest expanding therapeutic use exemptions, which require preapproval by medical professionals. Dr. Katherine McIntosh, a sports endocrinologist, stated, "A well-documented TUE process could bridge the gap between player health needs and policy enforcement."

The Kansas City Chiefs have not commented extensively on Johnson's suspension. Head coach Andy Reid said, "We support Nazeeh as he navigates this process and will continue to focus on the team’s preparation." Johnson's suspension comes during a challenging period for the Chiefs, who are contenders in the AFC but dealing with multiple injuries.

Johnson now faces the decision of whether to appeal the suspension, though success seems unlikely given the NFL’s history. His agent did not comment on potential legal action but expressed Johnson's frustration. "Nazeeh has always prided himself on his integrity," the agent said. "He hopes this situation prompts a conversation about how policies can evolve."

Calls for such discussions are likely to persist. As professional sports leagues balance competition integrity with player health, Johnson's case may influence future policy debates. The NFL's willingness to revisit its approach remains uncertain, but Johnson's experience illustrates the ongoing conflict between personal health and professional obligations.